10-K: Picard Medical widens 2025 loss, adds debt financing

Picard Medical posted a larger 2025 net loss amid modest revenue growth, completed a $19.6M IPO and issued $15M of senior secured notes with attached warrants as auditors flagged going-concern risk.

Summary

• Revenue rose 13% to $4.94 million in 2025 (Products $4.75M; Rentals $0.19M), with the U.S. representing 88% of sales.
• Gross loss was $0.20 million as total cost of revenues ($5.14M) exceeded revenue ($4.94M).
• Operating loss was $13.26 million; net loss widened 28% to $27.00 million versus $21.06 million in 2024.
• Operating cash burn increased to $15.67 million (2025); financing activities provided $27.08 million, ending cash and restricted cash totaled $11.45 million (cash $7.45M; restricted cash $4.00M).
• Completed IPO on Sept 2, 2025 (4,887,500 shares at $4.00; gross $19.6M; net $15.2M), plus a 637,500-share over-allotment on Sept 9, 2025 (net ~$2.4M).
• Entered a Dec 24, 2025 Securities Purchase Agreement; issued $15.0M senior secured notes on Dec 26, 2025 (due 2028) and warrants for 7,009,346 shares at $2.675; may issue up to an additional $35.0M of notes; placement agent received 700,934 warrants.
• At 12/31/2025, current liabilities were $18.70M, including fair value of senior secured note $5.45M and warrant liabilities $7.84M.
• Auditor included a going-concern explanatory paragraph; management disclosed material weaknesses in internal controls and significant future capital needs.
• Pipeline: first-in-animal trials for fully implantable Emperor TAH began Nov 2025; label expansion PMA supplement was converted to Panel Track (Mar 2025) with a decision expected in Q3 2026; Freedom+ driver PMA supplement under FDA review (Company anticipates approval by end of 2026).
• Legal: Putative securities class action (Louie v. Picard Medical, filed Feb 2, 2026) alleges IPO-related misstatements; Company disputes claims.

Sentiment

Score: 3

Explanation: StockSavvy.ai views the filing as risk-heavy: losses widened, cash burn remained high, and a going-concern warning persists despite new capital. Strategic assets and pipeline provide upside optionality but execution and financing risks dominate near term.

Positives

• Top-line growth of 13% to $4.94M, led by U.S. revenue (+$1.0M YoY).
• IPO completed with gross proceeds of $19.6M (net ~$15.2M) and over-allotment (net ~$2.4M), strengthening liquidity and enabling debt repayment to related parties (~$8.2M).
• Additional capital access via $15.0M senior secured notes issued Dec 26, 2025 with up to $35.0M more available subject to conditions.
• Emperor TAH program advanced to first-in-animal trials in Nov 2025; Company holds multiple next-generation TAH patents (e.g., U.S. Nos. 11,918,798; 12,121,711; 12,383,722; China 202080094390.7).
• MDSAP audit successfully completed in June 2025, supporting quality credentials.
• CMS coverage under DRG 001 and real-world clinical evidence underpin commercial use of SynCardia TAH in bridge-to-transplant.

Negatives

• Net loss increased 28% to $27.00M; operating loss $13.26M and gross loss $0.20M indicate lack of scale.
• Operating cash outflow rose to $15.67M; business remains dependent on external financing.
• Auditor raised substantial doubt about the Company’s ability to continue as a going concern; material weaknesses in internal control persist.
• High customer concentration (Customer A 43% of 2025 sales) and U.S. concentration (88% of revenue).
• Complex capital structure and earnings volatility from fair value accounting for the senior secured note and classification of warrants as liabilities ($7.84M at 12/31/2025).
• European CE mark under MDR not yet obtained (prior MDD CE mark cancelled in July 2022), limiting EU sales; China approval remains pending with uncertain timelines.
• Ongoing field safety correction related to driveline cannula wear; design change submission targeted Q3 2026.

Risks

• Substantial doubt about ability to continue as a going concern; additional funding is required to support operations.
• Significant volatility in results from fair value accounting for the senior secured note and classification of associated warrants as liabilities.
• Loss of, reduced purchases by, or delayed payments from highly concentrated customers and limited transplant centers.
• Reliance on single- or limited-source suppliers for critical components (e.g., Bimba/Heitek), with no long-term supply agreements; switching may require new regulatory approvals.
• EU MDR certification not yet obtained (prior MDD CE mark cancelled July 2022); MDR timelines are lengthy and uncertain.
• China NMPA approval remains uncertain; may require local testing and post-market studies.
• Manufacturing is complex and highly manual; workforce constraints, equipment failures, or noncompliance with FDA QSR could disrupt supply.
• Regulatory risks including delays, denials, or additional requirements for label expansion, long-term indication, next-gen drivers, and Emperor TAH.
• Device malfunctions or quality issues could trigger recalls, enforcement, reputational harm, and substantial costs (e.g., cannula tears; 114 reports as of Jan 29, 2026; no SAEs reported).
• Reimbursement/coverage uncertainties, especially outside the U.S.; adverse policy changes could reduce utilization.
• Cybersecurity threats could disrupt operations or trigger regulatory scrutiny and costs.
• Potential IP challenges; many current technologies rely on trade secrets rather than patents; outstanding royalties/security interest with Medtronic until ~$492K paid.
• Securities litigation risk (putative class action filed Feb 2, 2026).
• Controlled company status may reduce certain corporate governance protections for minority shareholders.

Future Outlook

Management plans to seek FDA label expansion (Panel Track PMA supplement decision expected in Q3 2026), pursue FDA approval of upgraded drivers (Company anticipates Freedom+ approval by end of 2026 and a next driver approval by mid-2027), continue animal testing of the fully implantable Emperor TAH (potential FDA approval as early as 2028), work toward MDR CE certification (targeting a 2027 submission), and progress China NMPA registration (feedback expected in 2026). All timelines are subject to regulatory review and may change.

Management Comments

• States an expectation to continue incurring losses for the foreseeable future and does not anticipate near‑term profitability.
• Identifies substantial doubt about the Company’s ability to continue as a going concern absent additional financing.
• Outlines a strategy to expand SynCardia TAH indications (e.g., bridge to candidacy, longer support), develop the fully implantable Emperor TAH, and advance next-generation driver technology.
• Notes material weaknesses in internal control over financial reporting and a remediation plan that includes adding accounting personnel and multi‑level review processes.

Industry Context

StockSavvy.ai notes that Picard operates in a niche TAH market with few competitors; Carmat’s Aeson device has EU approvals but faced insolvency proceedings in 2025, and BiVACOR is in early U.S. feasibility testing. LVADs from larger players (e.g., Abbott) remain the dominant MCS alternative. PMI’s unique FDA‑approved TAH and real‑world outcomes offer differentiation, but scale, global approvals, and reimbursement breadth are critical to compete.

Comparison to Industry Standards

• Against large-cap MCS peers (e.g., Abbott’s LVAD franchise), PMI’s ~$5M revenue base is de minimis and well below the scale typical for profitable medical device platforms.
• Carmat’s Aeson TAH has MDR certification in the EU, but operational continuity is uncertain after 2025 restructuring; PMI remains the only TAH with U.S. FDA PMA, a regulatory advantage domestically.
• BiVACOR is in early feasibility with no commercial approvals; PMI’s RWD and PMA status compare favorably on regulatory maturity but lag peers on manufacturing scale and margins.
• Gross margin and operating losses are materially below profitable medtech benchmarks; margin expansion depends on manufacturing efficiency, component sourcing security, and product upgrades.

Corporate Governance

Legal Proceedings

• Louie v. Picard Medical, Inc., et al., Case No. 5:26-CV-01024 (N.D. Cal., filed Feb 2, 2026): putative securities class action alleging IPO-related misstatements; Company disputes the claims; no estimate of loss.

Related Party Transactions

• Multiple related-party loans from Fang Family Fund entities during 2024–2025; many repaid post-IPO; one $1.0M loan dated Nov 26, 2025 was repaid Jan 6, 2026 (net of an overpaid interest receivable).
• Aggregated 2024 convertible note (~$7.0M) originally with a related party (Richard Fang/Fang Family Fund) was donated to two nonprofits and converted into common stock at IPO.
• Hunniwell-related working capital loans in 2025, including travel expense and severance loans, were repaid Sept 9, 2025.
• Entered a $0.7M related-party unsecured promissory note with Fang Family Fund, LLC – Series I on Feb 28, 2026 (6% interest; mandatory prepayment upon a qualified financing).

Stakeholder Impact

• Shareholders: Significant dilution from IPO, note-related warrants (7.0M+), and prior note conversions; potential further dilution from redemptions-in-stock and future capital raises.
• Creditors/Noteholders: Senior Secured Notes include monthly partial redemptions and a $4.0M minimum liquidity covenant, prioritizing near-term cash management.
• Customers/Patients: Field safety communication regarding cannula wear with instructions provided; design change planned via PMA supplement submission around Q3 2026.
• Suppliers: Single/limited-source dependencies (e.g., Bimba/Heitek) elevate continuity and quality risks given lack of long-term agreements.
• Employees: Continued emphasis on quality system compliance (MDSAP audit passed) and R&D execution, but resource constraints and going-concern risks could impact talent retention and hiring.

Next Steps

• Panel Track PMA supplement decision on label expansion expected in Q3 2026.
• Submit 180‑day PMA supplement to address cannula design change around Q3 2026 after validation.
• Pursue FDA approval of Freedom+ driver (Company anticipates by end of 2026) and next-generation driver (Company anticipates mid‑2027).
• Continue Emperor TAH animal trials through 1H 2026; longer-term pathway to potential FDA approval as early as 2028.
• Advance EU MDR CE Mark preparation (target 2027 submission) and China NMPA registration (feedback expected in 2026).
• Manage monthly partial redemptions on the Senior Secured Notes beginning Feb 1, 2026, via cash and/or stock per terms.

Key Dates

Recommendation

The Company retains a unique FDA-approved TAH platform and advancing pipeline, but losses, cash burn, a going-concern warning, customer/supplier concentration, governance overhang, and debt redemptions create substantial near-term risk. Maintain a neutral stance pending visibility on regulatory milestones, financing runway, and margin improvement.

Keywords

Picard Medical, SynCardia, Total Artificial Heart, TAH, Emperor TAH, Freedom Driver, Unicorn driver, PMA, Panel Track supplement, MDR CE Mark, NMPA China, DRG 001, MDSAP, Senior Secured Notes, Warrants, IPO, NYSE American: PMI, Going concern, Warrant liabilities, Mechanical circulatory support